{"created":"2023-06-20T15:47:24.170614+00:00","id":1938,"links":{},"metadata":{"_buckets":{"deposit":"3fe79246-0603-4e2f-b884-314513416f25"},"_deposit":{"created_by":4,"id":"1938","owners":[4],"pid":{"revision_id":0,"type":"depid","value":"1938"},"status":"published"},"_oai":{"id":"oai:hama-med.repo.nii.ac.jp:00001938","sets":["1:11"]},"author_link":["4927","4928"],"item_3_biblio_info_5":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"1989-11-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"11","bibliographicPageEnd":"1735","bibliographicPageStart":"1731","bibliographicVolumeNumber":"41","bibliographic_titles":[{"bibliographic_title":"日本産科婦人科學會雜誌","bibliographic_titleLang":"ja"}]}]},"item_3_description_9":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"卵巣癌の血清学的診断を行うために, 3種類の腫瘍マーカーCA 125, SLX, CA 72-4のcombination assayを行い, 各腫瘍マーカー単独の成績と比較し, さらに, 卵巣癌I期の症例については画像診断の精度と比較した. 1. Combinationassayによる卵巣癌患者の陽性率は90.3%であり, 臨床進行期別にはI期77.6%, II 期92.0%, III期98.5%およびIV期100.0%と漸増した. 組織型別には衆液性嚢胞腺癌93.8%, ムチン性嚢胞腺癌87.0%, 類内膜癌88.9%,および類中腎癌85.7%であつた. 一方, 正常者および良性疾患患者の偽陽性率はそれぞれ, 6.9%および38.6%であり良性疾患での偽陽性率が高値を示した. これは子宮腺筋症および外性子宮内膜症の偽陽性率がそれぞれ, 73.5%および57.1%と高いことに起因していると思われる. 2. 卵巣癌I期の58例について画像診断とcombination assayの精度を比較した結果, 画像診断とcombinationassayの両者とも癌を疑つた症例は38例, 65.5%, 画像診断で癌を疑いながらcombination assayで非癌と判定されたのは2例, 3.4%,画像診断で非癌と診断されながらcombinationassayで癌と判定されたのは7例, 12.1%,両検査法を行つても癌と判定できなかつたのは11例, 19.0%存在した. 画像診断で癌と診断された40例中38例はcombination assayにより癌と判定されているが, 一方, combination assayで癌と判定された45例中, 画像診断でも癌と診断されたのは38例であつた. 3種類の腫瘍マーカーの陽性率にはそれぞれ, 組織型別に特徴がありCA 125は漿液性癌に, SLXは類中腎癌に, CA 72-4はムチン性癌に高い陽性率を示しており, combination assayの有用性を認めた. また, 卵巣癌I期の症例について画像診断との比較を行つても遜色のない結果が得られた","subitem_description_language":"ja","subitem_description_type":"Abstract"}]},"item_3_publisher_6":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"日本産科婦人科学会","subitem_publisher_language":"ja"}]},"item_3_rights_7":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Copyright 日本産科婦人科学会","subitem_rights_language":"ja"},{"subitem_rights":"本文データは学協会の許諾に基づきCiNiiから複製したものである","subitem_rights_language":"ja"}]},"item_3_source_id_19":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"03009165","subitem_source_identifier_type":"ISSN"}]},"item_3_version_type_32":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"小林, 浩","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"川島, 吉良","creatorNameLang":"ja"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-08-27"}],"displaytype":"detail","filename":"sankafujinka-41_11-1731.pdf","filesize":[{"value":"536.1 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"sankafujinka-41_11-1731.pdf","url":"https://hama-med.repo.nii.ac.jp/record/1938/files/sankafujinka-41_11-1731.pdf"},"version_id":"3f7a988f-6387-4c74-8394-f71928879f98"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"CA 125","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"SLX","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"CA 72-4","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Combination assay","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Ovarian tumor","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"CA 125, SLXおよびCA 72-4による卵巣癌患者の判別","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"CA 125, SLXおよびCA 72-4による卵巣癌患者の判別","subitem_title_language":"ja"}]},"item_type_id":"3","owner":"4","path":["11"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2013-08-27"},"publish_date":"2013-08-27","publish_status":"0","recid":"1938","relation_version_is_last":true,"title":["CA 125, SLXおよびCA 72-4による卵巣癌患者の判別"],"weko_creator_id":"4","weko_shared_id":-1},"updated":"2023-08-02T07:20:04.491796+00:00"}